위암 치료제 시장 : 치료 분류, 치료 단계, 투여 경로, 제형, 치료법, 유통 채널별 - 세계 예측(2026-2032년)

The Gastric Cancer Drugs Market was valued at USD 4.31 billion in 2025 and is projected to grow to USD 4.58 billion in 2026, with a CAGR of 6.34%, reaching USD 6.63 billion by 2032.

A concise orientation to the evolving clinical and commercial ecosystem shaping gastric cancer therapeutics and strategic priorities for stakeholders

Gastric cancer remains a complex therapeutic area where biology, clinical practice, and health system policy intersect to shape patient outcomes. Recent years have seen a rapid evolution in how clinicians diagnose, stage, and treat gastric malignancies, driven by improved molecular characterization, broader adoption of multimodal therapy, and the introduction of immune and targeted agents. These developments have altered treatment pathways and created distinct opportunities and challenges for pharmaceutical developers, payers, and providers as they adapt to new efficacy and safety profiles and shifting standards of care.

This summary synthesizes the most relevant trends influencing therapeutic development and commercialization. It highlights changes in clinical paradigms, commercial dynamics, and regulatory patterns that are redefining value capture in gastric oncology. By focusing on actionable insights rather than raw market estimates, the narrative emphasizes the nexus between clinical evidence, treatment access, and strategic positioning. The aim is to equip executives, clinical leaders, and investor stakeholders with a concise but comprehensive orientation to the landscape so they can prioritize investments, refine go-to-market approaches, and anticipate near-term inflection points that will affect program viability and patient access.

How precision medicine, immuno-oncology advances, and evolving regulatory and reimbursement incentives are fundamentally reshaping gastric cancer treatment paradigms

The therapeutic landscape for gastric cancer is experiencing transformative shifts that span scientific innovation, regulatory approaches, and care delivery models. On the scientific front, the integration of precision oncology into standard workflows has accelerated; molecular subtyping and biomarker-driven patient selection are now routinely informing therapeutic decisions and trial design. This movement toward individualized therapy has elevated the importance of companion diagnostics and created demand for trials that demonstrate benefit in well-defined biomarker strata. Concurrently, immuno-oncology has extended into gastric cancer with checkpoint inhibitors and combinatorial regimens that aim to leverage synergy between targeted agents and the immune microenvironment.

Regulatory frameworks are adapting to these scientific advances by streamlining pathways for accelerated approval based on surrogate endpoints in populations with high unmet need, while simultaneously stressing post-approval evidence generation to confirm clinical benefit. Payers and health systems are responding by developing outcome-based contracting mechanisms and by scrutinizing real-world evidence to guide coverage decisions. These dynamics are catalyzing collaborative models where manufacturers, providers, and diagnostic developers align on evidence generation and reimbursement strategies. Together, these shifts are reshaping clinical trial priorities, commercial models, and investment strategies across the value chain.

Assessing the strategic supply chain, pricing, and access implications resulting from recent tariff changes and trade policy shifts affecting therapeutic inputs and finished products

In 2025, tariff policies affecting pharmaceuticals, components, and related biologics inputs introduced a new layer of complexity across global supply chains and commercial operations. Tariff adjustments have the potential to increase landed costs for imported active pharmaceutical ingredients, laboratory consumables, and certain finished formulations, exerting pressure on manufacturing footprints and procurement strategies. Manufacturers with globally dispersed supply chains must reassess supplier contracts and consider options such as nearshoring, dual sourcing, and increased inventory buffering to mitigate exposure to tariff-driven price volatility.

The cumulative impact is felt across procurement, pricing, and market access. Hospitals and health systems that rely on international suppliers may face higher acquisition costs, which can translate into tighter formulary negotiations and more rigorous health technology assessments. Manufacturers are incentivized to optimize manufacturing locality and to invest in supply chain transparency to support cost-containment discussions with payers. In parallel, companies may accelerate conversations about value-based agreements that decouple price from volume and focus reimbursement on demonstrated clinical outcomes. These shifts also create opportunities for regional manufacturing partnerships and for suppliers that can demonstrate tariff-resilient sourcing and rapid quality assurance processes. Ultimately, tariff changes increase the strategic importance of supply chain agility and evidence that supports durable access in affected markets.

Segment specific insights that connect therapeutic class, line of therapy, distribution pathway, administration route, dosage formulation, and therapy composition to clinical and commercial implications

Segmenting the gastric cancer therapeutics landscape clarifies where clinical value and commercial opportunity intersect, and it highlights how different product characteristics influence adoption and positioning. Based on therapeutic class, Biologics including cytokines and monoclonal antibodies, Chemotherapy including fluoropyrimidines, platinum-based agents, and taxanes, Immunotherapy encompassing cancer vaccines and checkpoint inhibitors, and Targeted Therapy with Her2 inhibitors and Vegf inhibitors each have distinct development pathways and evidence requirements, and they interact with diagnostics, combination strategies, and safety monitoring in unique ways. The differentiation between biologic subclasses matters for manufacturing complexity and regulatory expectations, while the established roles of chemotherapy anchor many combination regimens and influence line-of-therapy decisions.

Based on treatment line, differences between first line, second line, and third line or later therapies govern trial design, comparator selection, and the magnitude of unmet need that a new therapy must address. First-line innovations typically require broader safety tolerability and demonstrable improvement in survival or quality of life, whereas later-line agents may gain approval based on smaller, biomarker-enriched populations with clinically meaningful responses. Based on distribution channel, the split between hospital pharmacies and retail pharmacies affects channel economics, patient access points, and the logistics of reimbursement and adherence support. Based on route of administration, the divergence among intravenous, oral, and subcutaneous modalities has implications for site-of-care, patient convenience, adherence, and cost structures, with oral and subcutaneous options often enabling outpatient management and potential shifts away from infusion center utilization.

Based on dosage form, considerations around capsules, lyophilized powder, pre-filled syringe, and tablets extend beyond patient preferences to stability, cold chain logistics, and compounding requirements, which in turn influence procurement and inventory policies. Finally, based on therapy type, the strategic choices between combination therapy and monotherapy drive clinical development complexity, regulatory interactions, and commercial narratives; combination regimens can deliver incremental efficacy but require careful safety management and co-development coordination. Taken together, these segmentation lenses provide a structured framework to prioritize development programs, design differentiated clinical trials, and craft market access strategies that align product attributes with clinical practice and payer expectations.

How regional regulatory diversity, payer frameworks, and healthcare infrastructure dictate differentiated market access and commercialization strategies across major global regions

Regional dynamics play a pivotal role in shaping development priorities, regulatory strategy, and commercialization approaches for gastric cancer therapies. In the Americas, regulatory convergence and established oncology networks support rapid adoption of innovations that demonstrate clear clinical benefit, yet payer scrutiny and value assessment frameworks require robust outcomes evidence and price-value alignment. Health systems in the region are also increasingly receptive to real-world evidence generation and value-based purchasing pilots that can enable earlier patient access while managing budget impact.

In Europe, Middle East & Africa, heterogeneity across regulatory environments and reimbursement pathways necessitates tailored market access strategies and flexible pricing models. While some jurisdictions exhibit strict health technology assessment protocols with cost-effectiveness thresholds, others prioritize access through managed entry agreements or conditional reimbursement linked to post-market evidence. Capacity constraints and variations in diagnostic availability in parts of the region underscore the need for deployment plans that include diagnostic enablement and capacity building to realize the full potential of targeted therapies. In Asia-Pacific, high incidence rates in certain countries, combined with rapidly modernizing clinical infrastructure, create strong demand for therapies that address region-specific molecular epidemiology. Regulatory authorities across Asia are increasingly harmonizing pathways and engaging in expedited review processes for priority medicines, while local manufacturing and licensing partnerships remain central to scaling access and managing commercial risk. Across all regions, alignment between evidence generation, pricing approaches, and delivery infrastructure is essential to convert clinical innovation into broader population impact.

Insights into how research focus, partnership structures, diagnostic integration, and manufacturing strategies differentiate company competitive positioning in gastric cancer therapeutics

Company strategies in gastric cancer therapeutics are diverging along research intensity, portfolio breadth, and partnership models. Some organizations concentrate R&D investment on next-generation targeted agents and biomarker discovery, prioritizing programs that enable narrow indication approvals but high clinical impact. Others pursue combination regimens that pair established chemotherapeutics with immuno-modulatory agents to enhance response durability in broader populations. A growing subset of companies is emphasizing diagnostic co-development and commercial bundling to support precise patient selection and to accelerate reimbursement acceptance.

Commercially, leading firms are experimenting with differentiated pricing approaches, evidence generation partnerships, and lifecycle management strategies that extend utility through new dosage forms or administration routes. Strategic alliances between biotechnology innovators and larger specialty pharmaceutical companies continue to be a dominant model for scaling manufacturing, regulatory submissions, and global commercialization. Additionally, companies with integrated manufacturing capabilities and regional production footprints are better positioned to navigate trade policy shifts and to respond rapidly to formulary decisions. Across the ecosystem, success increasingly depends on demonstrating meaningful patient benefit in real-world settings and on establishing collaborative arrangements with providers and payers to align incentives around value and access.

Practical and high impact strategic actions for developers and commercial leaders to secure clinical adoption, supply chain resilience, and payer alignment in gastric cancer care

Industry leaders seeking to strengthen their position in gastric cancer therapeutics should prioritize integrated strategies that align scientific differentiation with operational resilience and payer engagement. First, invest early in biomarker discovery and companion diagnostic partnerships to maximize the clinical and commercial returns of targeted and immuno-modulatory programs. Diagnostics are critical enablers of precision labeling and help build compelling dossiers for reimbursement discussions. Second, redesign supply chains for greater flexibility by diversifying sourcing, exploring regional manufacturing options, and implementing digital traceability to mitigate tariff and trade risks while improving procurement predictability.

Third, develop evidence generation plans that combine randomized trials with pragmatic real-world studies to address payer concerns about generalizability and long-term outcomes. Purposeful post-approval data collection can unlock managed entry agreements and outcome-based contracts. Fourth, evaluate administration route and dosage form innovation not only through a clinical lens but also as a commercial lever to shift site-of-care, improve adherence, and reduce total cost of care. Fifth, pursue value-focused pricing strategies and commercial models that emphasize demonstrable improvements in survival, quality of life, or healthcare utilization, enabling constructive dialogues with payers and health systems. By implementing these actions in a coordinated manner, organizations can reduce execution risk and accelerate the translation of clinical advances into sustained patient access.

A transparent multi-source methodology combining clinical evidence review, regulatory and payer analysis, and expert validation to derive robust actionable insights

This research synthesized publicly available clinical literature, regulatory decisions, guideline updates, and expert interviews to build a multi-dimensional perspective on gastric cancer therapeutics. The approach combined qualitative thematic analysis of peer-reviewed clinical studies and conference data with structured interviews of oncologists, pharmacoeconomists, and supply chain specialists to capture operational and access considerations. Regulatory pathways and policy developments were reviewed across major jurisdictions to understand approval trends and post-market evidence expectations, and payer literature was examined to identify common value assessment criteria and contracting practices.

Where appropriate, secondary sources were cross-checked against primary documents such as clinical trial protocols, regulatory agency summaries, and professional society guideline statements to ensure factual accuracy. Expert validation workshops were used to refine interpretations and to prioritize strategic implications. The methodology emphasized triangulation across evidence streams and transparent documentation of assumptions to provide stakeholders with a credible and actionable synthesis rather than speculative projections.

A synthesis of key conclusions emphasizing integrated evidence, manufacturing agility, and payer collaboration as the determinants of successful therapeutic adoption in gastric oncology

Gastric cancer therapeutics are at an inflection point where scientific opportunity meets complex operational and policy realities. Innovations in targeted therapies, immuno-oncology, and formulation science promise improved outcomes for defined patient populations, yet achieving broad and sustainable access will require deliberate alignment of evidence generation, supply chain strategy, and value demonstration. Stakeholders that proactively invest in diagnostics, agile manufacturing, and pragmatic evidence generation will be better positioned to convert clinical innovation into durable clinical and commercial impact.

Looking ahead, the most successful programs will be those that integrate clinical differentiation with operational readiness and that engage payers and providers early to co-design access pathways. By focusing on these integrated priorities, organizations can reduce uncertainty, accelerate adoption, and ultimately improve therapeutic options for patients living with gastric cancer.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gastric Cancer Drugs Market, by Therapeutic Class

• 8.1. Biologics
  • 8.1.1. Cytokines
  • 8.1.2. Monoclonal Antibodies
• 8.2. Chemotherapy
  • 8.2.1. Fluoropyrimidines
  • 8.2.2. Platinum-Based Agents
  • 8.2.3. Taxanes
• 8.3. Immunotherapy
  • 8.3.1. Cancer Vaccines
  • 8.3.2. Checkpoint Inhibitors
• 8.4. Targeted Therapy
  • 8.4.1. Her2 Inhibitors
  • 8.4.2. Vegf Inhibitors

9. Gastric Cancer Drugs Market, by Treatment Line

• 9.1. First Line
• 9.2. Second Line
• 9.3. Third Line Or Later

10. Gastric Cancer Drugs Market, by Route Of Administration

• 10.1. Intravenous
• 10.2. Oral
• 10.3. Subcutaneous

11. Gastric Cancer Drugs Market, by Dosage Form

• 11.1. Capsules
• 11.2. Lyophilized Powder
• 11.3. Pre-Filled Syringe
• 11.4. Tablets

12. Gastric Cancer Drugs Market, by Therapy Type

• 12.1. Combination Therapy
• 12.2. Monotherapy

13. Gastric Cancer Drugs Market, by Distribution Channel

• 13.1. Hospital Pharmacies
• 13.2. Retail Pharmacies

14. Gastric Cancer Drugs Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Gastric Cancer Drugs Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Gastric Cancer Drugs Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. United States Gastric Cancer Drugs Market

18. China Gastric Cancer Drugs Market

19. Competitive Landscape

• 19.1. Market Concentration Analysis, 2025
  • 19.1.1. Concentration Ratio (CR)
  • 19.1.2. Herfindahl Hirschman Index (HHI)
• 19.2. Recent Developments & Impact Analysis, 2025
• 19.3. Product Portfolio Analysis, 2025
• 19.4. Benchmarking Analysis, 2025
• 19.5. AbbVie Inc.
• 19.6. Amgen Inc.
• 19.7. Astellas Pharma Inc.
• 19.8. AstraZeneca PLC
• 19.9. Bayer AG
• 19.10. Biogen MA Inc.
• 19.11. Boehringer Ingelheim GmbH
• 19.12. Bristol-Myers Squibb Company
• 19.13. Cipla Limited
• 19.14. Eli Lilly and Company
• 19.15. F. Hofmann-La Roche Ltd.
• 19.16. Gilead Sciences, Inc.
• 19.17. GlaxoSmithKline PLC
• 19.18. Incyte Corporation
• 19.19. Ipsen Pharma
• 19.20. Johnson & Johnson Services, Inc.
• 19.21. Mallinckrodt PLC
• 19.22. Merck KGaA
• 19.23. Novartis AG
• 19.24. Pfizer, Inc.
• 19.25. Regeneron Pharmaceuticals, Inc.
• 19.26. Sanofi Group
• 19.27. Sumitomo Pharma Co., Ltd.
• 19.28. Sun Pharmaceuticals Limited
• 19.29. Takeda Pharmaceutical Company Limited
• 19.30. Teva Pharmaceutical Industries Ltd.